Sign In
Buy ZYNE
$1.30
+0 (+0%)
At Close: Jan 09, 2024
Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children
11:06am, Thursday, 09'th Sep 2021
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment
Zynerba presents longer-term tolerability and efficacy data of Zygel in children and adolescents with autism spectrum disorder
09:12am, Thursday, 09'th Sep 2021
Zynerba Pharmaceuticals Inc. has presented data from the Phase 2 BRIGHT trial describing the tolerability and efficacy of its Zygel transdermal cannabinoid therapy in children and adolescents with aut
DEVON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Zynerba Pharmaceuticals says results of Phase 2 BELIEVE open-label study of Zygel described as positive in medical journal
08:36am, Tuesday, 07'th Sep 2021
Zynerba Pharmaceuticals Inc told investors that an article in the Journal of the American Medical Association (JAMA) Network Open had described the results of the company's open-label Phase 2 BELIEVE
Zynerba Pharmaceuticals Inc says results of Phase 2 BELIEVE open-label study of Zygel described as positive in medical journal
08:23am, Tuesday, 07'th Sep 2021
Zynerba Pharmaceuticals Inc told investors that an article in the Journal of the American Medical Association (JAMA) Network Open had described the results of the company's open-label Phase 2 BELIEV
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
07:30am, Thursday, 02'nd Sep 2021
DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Zynerba Pharmaceuticals stock “presents a potentially significant opportunity for patient investors,” says Canaccord Genuity
01:24pm, Monday, 23'rd Aug 2021
In a note to clients on August 20, Canaccord Genuity analysts reiterated their ‘Buy' rating and $9 target price on shares of Zynerba Pharmaceuticals Inc, saying “ZYNE stock presents a potentially
A Week's Worth of Actionable Cannabis Stock News
08:14am, Monday, 16'th Aug 2021
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape
Zynerba's CBD skin gel Zygel offers a potential goldmine of therapies for Fragile X syndrome and other conditions
07:30pm, Tuesday, 10'th Aug 2021
Focused on treating rare epilepsies and neuropsychiatric disorders Lead candidate Zygel offers a goldmine of therapies for multiple conditions Initiating RECONNECT trial with Zygel for Fragile X syndr
Zynerba Pharmaceuticals flush with $85.8M in 2Q to fund pivotal trials of its flagship Zygel CBD gel
12:14pm, Monday, 09'th Aug 2021
Zynerba Pharmaceuticals Inc has posted second-quarter results with ample cash on hand, which gives the company a long runway to run pivotal trials of its flagship product Zygel (ZYN002), a patent-prot
Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights
07:00am, Monday, 09'th Aug 2021
DEVON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference
07:30am, Wednesday, 04'th Aug 2021
DEVON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Why Weed Penny Stocks Are Up Today & 3 to Watch as Tilray Skyrockets
12:35pm, Wednesday, 28'th Jul 2021
Which marijuana penny stocks are investors watching after Tilray's spike today? The post Why Weed Penny Stocks Are Up Today & 3 to Watch as Tilray Skyrockets appeared first on Penny Stocks to Buy, Pic
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference
07:30am, Wednesday, 07'th Jul 2021
DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare
Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies
02:44pm, Friday, 11'th Jun 2021
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (A
